PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-488.33%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
-14.77%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-14.77%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
-25.91%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
18928.57%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
439.10%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
10.94%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
70.03%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-47.20%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
11.95%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
11.92%
EPS growth while CRVO declines. John Neff would investigate advantages.
11.92%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.